Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 27 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 55%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $163,558, and 22 are calls, for a total amount of $1,426,699.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $340.0 for Amgen over the recent three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1080.41 with a total volume of 2,179.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $230.0 to $340.0 over the last 30 days.
Amgen 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 06/28/24 | $12.5 | $11.4 | $12.5 | $312.50 | $188.7K | 283 | 50 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $57.25 | $54.5 | $56.15 | $280.00 | $174.0K | 1.7K | 21 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $57.1 | $54.5 | $56.15 | $280.00 | $140.3K | 1.7K | 65 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $56.4 | $54.15 | $55.85 | $280.00 | $106.1K | 1.7K | 2 |
| AMGN | CALL | SWEEP | BULLISH | 07/19/24 | $10.15 | $8.95 | $10.15 | $320.00 | $101.5K | 2.4K | 4 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen's Current Market Status
- With a trading volume of 1,172,634, the price of AMGN is up by 0.34%, reaching $319.24.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 37 days from now.
What Analysts Are Saying About Amgen
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $332.0.
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Amgen, targeting a price of $332.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
